“…Since the approval by the Food and Drug Administration in 2008, multiple prospective US studies have reported safety data (7)(8)(9)(10). However, in clinical practice, outside of controlled clinical trials, a number of case reports have documented severe adverse events (AEs) with regadenoson for MPI stress testing, e.g., advanced heart block, asystole, and acute myocardial infarction (MI) (11)(12)(13)(14). These safety issues have led to some concerns in the medical community (15).…”